Altre lingue Vaxxinity, Inc.

Azioni

VAXX

US92244V1044

Mercato chiuso - OTC Markets Altri mercati azionari 21:56:23 31/05/2024			Variaz. 5gg	Var. 1 gen.
0,0783 ^USD	-5,65%		-2,12%	-90,79%

27/03	Vaxxinity, Inc. riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023	CI
07/03	Vaxxinity annuncia dati positivi sul coinvolgimento del target nello studio clinico di Fase 1 per la malattia di Parkinson a AD/PD? 2024	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Vaxxinity, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson?s Disease at AD/PD? 2024	07/03
Vaxxinity, Inc. Announces the Publication of Data from Multiple Non-Human Primate Studies	15/02
Vaxxinity, Inc. to Present Data from UB-312 Program in Parkinson's Disease at International Conference on Alzheimer's and Parkinson's Diseases and Related Neurolog Disorders	13/02
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida	30/01
Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida	18/01
Vaxxinity, Inc. Announces Resignation of Katherine Eade from the Board of Directors	01/12
Researchers return to Alzheimer's vaccines, buoyed by recent drug success	20/11
Vaxxinity, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
Vaxxinity, Inc. Announces Executive Changes	28/09/23
VAXXINITY, INC. : Baird désormais positif sur le dossier	08/09/23
Vaxxinity, Inc. Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer's Disease	10/08/23
Vaxxinity, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23
Vaxxinity, Inc. Announces Executive Changes	27/07/23
Vaxxinity Says B-312 Phase 1 Trial Shows Target Engagement of Toxic Alpha-Synuclein in Parkinson's Patients; Shares Rise	17/07/23
Vaxxinity, Inc. Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson's Patients	17/07/23
Vaxxinity Reports 'Positive' Results in Early-Stage Parkinson's Disease Trial	22/06/23
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson's Disease	22/06/23
Vaxxinity, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/05/23
Vaxxinity, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	27/03/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Vaxxinity, Inc.

Azioni

VAXX

US92244V1044

Altre lingue

Filtri